| | | I | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 首页 | 机构概况 | 新闻动态 | 政务公开 | 政务服务 | 政民互动 | 阳光药监 | 〇 请输入您搜索的内孙 | 特此通告。 黑龙江省药品监督管理局 2025年12月16日 附件 根据《国家药监局 农业农村部 国家林草局 国家中医药局关于发布<中药材生产质量管理规范>的公告》（2022年第22号）和《黑龙江省药品监督管理局 黑 龙江省农业农村厅 黑龙江省林业和草原局 黑龙江省中医药管理局关于推动实施<中药材质量管理规范>的通告》的要求，2025年11月25日至11月27日，我局 组织对黑龙江葵花药业股份有限公司基地开展延伸检查（中药材符合性检查），结果为符合GAP要求。 中药材GAP符合性延伸检查结果 | 被检 | 被检查 | 中 药 | | 基地面 | | 经纬度 | 本次检 | 检 查 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 查 | | | 基地建 | | 基地地 | | 查预 ...

重庆市药品监督管理局关于中药材GAP符合性信息的通告 根据《国家药监局 农业农村部 国家林草局 国家中医药局关于发布〈中药材生产质量管理规范〉的公告》（2022年第22号）和《重庆市药品监督管理局实施 中药材生产质量管理规范工作指导原则》（渝药监〔2023〕36号）精神，太极集团重庆桐君阁药厂有限公司对其甘草药材供应商内蒙古塞外朔漠中药材有限 公司（合作方：重庆中药材有限公司）开展了审核检查，认为符合GAP要求。我局对太极集团重庆桐君阁药厂有限公司的GAP自评材料进行了审核，符合要 求，现予通告。 中药材GAP符合性信息 | 药品生产企业 | 中成药/饮片 | 中药 材 | 中药材种植 | | 基地面积 | 检 查 | | --- | --- | --- | --- | --- | --- | --- | | 名称 | 品种 | 品种 | 企业 | 基地地址 | （亩） | 结 | | | | | | | | 果 | | | 沉香化气片 | | | | | | | | 四君子合剂 | | | | | | | | 桔贝合剂 | | | | | | | | 龙胆泻肝片 | | | | | | | | 黄连上清丸 ...

Core Insights - The traditional Chinese medicine (TCM) market is entering a critical period for production and sales, facing ongoing adjustments due to intensified supply-demand conflicts and strengthened policy guidance [1] Group 1: Supply and Demand Dynamics - The peak production period is expected to lead to a significant short-term increase in supply, with an estimated total production of approximately 5.8 million tons by 2025, while market demand is only about 5 million tons, resulting in an overall surplus rate of 16% [2] - The autumn harvest season in October will further highlight the supply-demand imbalance, leading to continued pressure on market prices [2] - Major varieties such as Angelica, Astragalus, and Codonopsis are expected to see a significant increase in supply as new crops are harvested [2] Group 2: Procurement Strategies and Price Adjustments - Under the backdrop of centralized procurement, TCM companies are adopting conservative procurement strategies to control raw material costs, with the second round of national centralized procurement for TCM decoction pieces already initiated [3] - This centralized procurement is expected to cover a wider range of products, prompting companies to reduce costs and improve efficiency through standardization, indicating a new round of price adjustments in the TCM industry [3] - The price bottoming trend for TCM materials may persist until the end of 2025 or even into 2026, particularly as root and rhizome materials are fully harvested [3] Group 3: Industry Transformation and Quality Standards - The TCM industry is accelerating its transformation, with initiatives like Zhejiang's "Zhejiang Eight Flavors" project aimed at establishing quality standards for TCM materials [4] - The implementation of Good Agricultural Practices (GAP) for TCM is being promoted nationwide to ensure quality, with various regions actively developing GAP bases [4] - Companies are increasingly focusing on establishing high-standard TCM planting bases to ensure the quality and traceability of authentic medicinal materials, which is crucial for building product barriers and advancing the modernization of TCM [5][6] Group 4: Long-term Industry Outlook - The TCM market is currently in a deep adjustment phase due to multiple factors, including production pressure, weak demand, capital withdrawal, and policy guidance [6] - The industry is expected to gradually move towards a path of standardization, branding, and quality improvement, with "high quality and high price" becoming the mainstream trend [6] - Industry participants are encouraged to adapt to policy directions and focus on high-quality and specialty varieties to seize opportunities in the ongoing industry restructuring [6]

Group 1 - The announcement by the National Medical Products Administration and other authorities regarding the compliance of traditional Chinese medicine (TCM) material production quality management standards is highlighted [2] - Taiji Group Chongqing Fuling Pharmaceutical Factory and Chongqing Traditional Chinese Medicine Slice Factory have conducted audits on their supplier, Zhalantun Tianli Agricultural and Sideline Products Purchase and Sale Co., Ltd., and found it compliant with GAP requirements [2] - A comprehensive evaluation of the TCM materials used by Taiji Group and Chongqing Traditional Chinese Medicine Slice Factory confirmed compliance with the "Traditional Chinese Medicine Material Production Quality Management Standards" [2] Group 2 - The compliance information table indicates that Taiji Group Chongqing Fuling Pharmaceutical Factory produces "Huo Xiang Zheng Qi Oral Liquid" and uses Zhalantun Tianli as a supplier for "Cang Zhu" material [3] - The planting base for "Cang Zhu" is located in Inner Mongolia, with an area of 5060 mu [3] - Chongqing Traditional Chinese Medicine Slice Factory is also involved in the production of "Cang Zhu" slices, confirming the compliance of their material sourcing [3]

Group 1 - The core viewpoint emphasizes the transformation of traditional Chinese medicine (TCM) through technology and the establishment of a comprehensive industrial chain in the medicinal herb sector in Weiyuan, Gansu Province [1][2][4] - Gansu Baishitang Organic Traditional Chinese Medicine Co., Ltd. utilizes a "dragon head enterprise + cooperative + processing workshop + base + farmers" model for full digital management from planting to harvesting [2][3] - The "six unifications traceable" management model has been implemented, ensuring standardized production and traceability of medicinal herbs, enhancing the quality and safety of TCM products [2][4] Group 2 - Weiyuan County plans to establish 68,000 acres of GAP bases by 2024, accounting for 29.4% of the total in Gansu Province, with a target of 133,000 acres by 2025 [2] - The county has invested 340 million yuan in a provincial economic development zone, attracting 76 deep processing enterprises and processing over 8,000 tons of fresh medicinal materials annually [4] - The geographical indication brand value of "Weiyuan White Strip Ginseng" has reached 1.976 billion yuan, with 24 enterprises using this brand to develop a diverse range of products [4]